| Name | Title | Contact Details |
|---|
Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.
Joule has pioneered a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Free of feedstock constraints and complex processing, this platform can achieve unrivaled scalability, volumes and costs without the use of any agricultural land, fresh water or crops. Unlike products derived with complexity from petroleum or biomass, Joule Sunflow® products are produced in a direct, continuous process from abundant resources. The novel CO2-to-liquids conversion requires only sunlight, non-potable water and engineered bacteria that function as living catalysts to produce specific products, including ethanol and hydrocarbon fuels that are inherently compatible with existing infrastructure. Joule’s highly efficient process and production system are well suited for deployment around the world, unhindered by land or resource constraints. This uniquely modular system can achieve replicable productivity, whether installed across 100 or 1,000 acres, mitigating scale-up risks and ensuring stability of supply. At full-scale commercialization in ideal locations, the company ultimately targets 25,000 US gallons of Joule Sunflow®-E (solar ethanol) or 15,000 US gallons of Joule Sunflow®-D (solar diesel) per acre annually, for approximately $1.20/US gallon ($50/barrel). Joule has successfully pilot-tested its platform for over two years, initiated demonstration-scale operations, and assembled a specialized team to lay the groundwork for commercial deployment. The company is moving rapidly to commercialize Joule Sunflow-E, with Joule Sunflow-D and additional hydrocarbon fuels to follow. Joule is privately held and has raised approximately $200 million in funding to date. The company was founded within Flagship VentureLabs™, and operates out of Bedford, Massachusetts and The Hague, The Netherlands, with production operations in Hobbs, New Mexico.
BioDuro-Sundia provide its biopharma customers a single end-to-end solution from early stage drug discovery to late stage manufacturing.
The Laboratory for Advanced Medicine, Inc. (LAM) is a bio-pharmaceutical company dedicated to developing revolutionary non-invasive, non-toxic technologies for disease diagnosis and intervention, with an emphasis on cancer.
CardioVascular BioTherapeutics, Inc. is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.